ArticleNature2023
Antiviral type III CRISPR signalling via conjugation of ATP and SAM.
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 51 citations in OpenAlex.
- Cyclic tri-adenylate controls a CARF-TM effector in type II Panoptes anti-phage systems.PLoS biology · 2026Article
- Review
- Bacterial and human exonucleases mediate interkingdom antiviral immunity.bioRxiv : the preprint server for biology · 2026Article
- Molecular basis of SAM-AMP synthesis and degradation in the type III-B CRISPR-Cas system.Nature chemical biology · 2026Article
- Structural mechanism of SAM-AMP and SAM-AMPNature communications · 2026Article
- Functional diversity of phage sponge proteins that sequester host immune signals.Nature microbiology · 2026Article
- The CRISPR ring nuclease Csx15 oligomerises on cyclic nucleotide binding to regulate antiviral defence.The Biochemical journal · 2026Article
- Mechanistic basis for selective Csm6-2 activation by cyclic penta-adenylate in a type III CRISPR-Cas system.The EMBO journal · 2026Article
- Periplasmic gatekeeping of phage DNA entry by an rSAM enzyme matured effector with HxS repeats.Nature communications · 2026Article
- Structural and functional insights into the adenosine deaminase of the type III-B CRISPR-Cas system.Nucleic acids research · 2026Article
- Structural plasticity enables broad cAn binding and dual activation of CRISPR-associated ribonuclease Cdn1.Nucleic acids research · 2026Article
- Manipulation of the nucleotide pool in human, bacterial and plant immunity.Nature reviews. Immunology · 2026Review
- Structure and mechanism of the broad spectrum CRISPR-associated ring nuclease Crn4.Nature communications · 2025Article
- Divergent viral phosphodiesterases for immune signaling evasion.Cell host & microbe · 2025Article
- Carboxymethylcytosine is a natural base modification and a handle for bacteriophage DNA hypermodification.Nature communications · 2025Article
- An updated evolutionary classification of CRISPR-Cas systems including rare variants.Nature microbiology · 2025Article
- Molecular mechanisms of CBASS phospholipase effector CapV mediated membrane disruption.Nature communications · 2025Article
- Diversity and abundance of ring nucleases in type III CRISPR-Cas loci.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- SAM-AMP lyases in type III CRISPR defence.Nucleic acids research · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR systems are widespread in the prokaryotic world, providing adaptive immunity against mobile genetic elements
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.